Danisco and NattoPharma sign global agreement on MenaQ7

Danisco and NattoPharma have entered into long term global supply,
marketing and license agreements securing Danisco rights as
NattoPharma's sole partner in marketing the natural vitamin K2
product MenaQ7® to the global food industry.
 
MenaQ7 contains one of the most bioavailable forms of natural Vitamin
K2, known as menaquinone-7. It is extracted from Natto, the
traditional japanese fermented soy bean, which has been consumed in
Japan for hundreds of years for its health benefits.
 
"MenaQ7 complements our portfolio of health ingredients and fits well
with our strategic focus on Health and Nutrition," comments Fabienne
Saadane-Oaks, President of Danisco BioActives. "The agreement will
contribute to strengthening our range of products for cardiovascular
health in addition to opening a new platform for bone health."
"The agreement represents a major commercial breakthrough for
NattoPharma," states Thomas Christensen, President and Chief
Executive Officer of NattoPharma, a Norway-based company and
exclusive supplier of MenaQ7. "Danisco is one of the world's leading
suppliers of food ingredients and our partnership will allow for
high-volume production and supply of our unique product MenaQ7 to the
fast-growing food fortification industry."
 
The agreement does not cover distribution in Norway, where
NattoPharma will market the product directly to food manufacturers.
 
The parties have agreed not to disclose details of the agreement.
 
For more information, please contact:
Danisco:        nathalie.brosse@danisco.com, ph +33156604726
NattoPharma: Thomas.christensen@nattopharma.com, ph. +4792255444
 
This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.